Background: Clinical features and treatment outcomes of intravascular large B-cell lymphoma (IVLBCL) have rarely been reviewed due to its rarity and pathologic obscurity. Methods: We analyzed 20 patients who were pathologically diagnosed with IVLBCL at the Samsung Medical Center. Results: Initial manifestations were nonspecific, such as fever with cytopenia, elevated serum lactate dehydrogenase and hypoalbuminemia. Hemophagocytosis was frequent and bone marrow was the most common site of pathologic diagnosis in our series. Hepatosplenomegaly, pleural effusion and ground-glass opacity in the lungs were also commonly found, and positron emission tomography imaging showed increased 18F-fluorodeoxyglucose uptake in the involved organs. All patients received CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or rituximab-CHOP. The median overall survival (OS) was 38.9 months (95% confidence interval 6.7-71.1). Rituximab-containing chemotherapy compared to chemotherapy alone resulted in higher 3-year OS (71.4 and 25.0%; p = 0.027). Patients with hemophagocytosis had a poorer 3-year OS compared to patients without hemophagocytosis (29.6 and 75%; p = 0.046). Prognostic factor analysis showed the association of pleural effusion with worse OS (p = 0.002). Conclusions: Treatment with rituximab-containing chemotherapy can improve the treatment outcome of IVLBCL. Pleural effusion may be a poor prognostic factor in patients with IVLBCL.

Keywords:
Intravascular B-cell lymphoma, Positron emission tomography/computerized tomography, Rituximab
1.
Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S: Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007;25:3168-3173.
2.
Shimada K, Kinoshita T, Naoe T, Nakamura S: Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009;10:895-902.
3.
Ferreri AJ, Campo E, Ambrosetti A, Ilariucci F, Seymour JF, Willemze R, Arrigoni G, Rossi G, Lopez-Guillermo A, Berti E, Eriksson M, Federico M, Cortelazzo S, Govi S, Frungillo N, Dell'Oro S, Lestani M, Asioli S, Pedrinis E, Ungari M, Motta T, Rossi R, Artusi T, Iuzzolino P, Zucca E, Cavalli F, Ponzoni M: Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol 2004;15:1215-1221.
4.
Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru J, Kojima M, Miura I, Mori N, Yoshino T, Nakamura S: Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478-485.
5.
Matsue K, Asada N, Odawara J, Aoki T, Kimura S, Iwama K, Fujiwara H, Yamakura M, Takeuchi M: Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma. Ann Hematol 2011;90:417-421.
6.
Masaki Y, Dong L, Nakajima A, Iwao H, Miki M, Kurose N, Kinoshita E, Nojima T, Sawaki T, Kawanami T, Tanaka M, Shimoyama K, Kim C, Fukutoku M, Kawabata H, Fukushima T, Hirose Y, Takiguchi T, Konda S, Sugai S, Umehara H: Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 2009;89:600-610.
7.
Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalban C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, Ponzoni M: The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western' patients with intravascular large B-cell lymphoma. Br J Haematol 2008;143:253-257.
8.
Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T: Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008;26:3189-3195.
9.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
10.
Ferreri AJ, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalban C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A, Pertoldi B, Horvath B, Szomor A, Zucca E, Cavalli F, Ponzoni M: Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007;92:486-492.
11.
Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, Lopez-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M, International Extranodal Lymphoma Study G: Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant'. Br J Haematol 2004;127:173-183.
12.
Asada N, Odawara J, Kimura S, Aoki T, Yamakura M, Takeuchi M, Seki R, Tanaka A, Matsue K: Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 2007;82:1525-1527.
13.
Sukpanichnant S, Visuthisakchai S: Intravascular lymphomatosis: a study of 20 cases in Thailand and a review of the literature. Clin Lymphoma Myeloma 2006;6:319-328.
14.
Takahashi Y, Iida K, Hino Y, Ohara T, Kurahashi T, Tashiro T, Chihara K: Silent intravascular lymphoma initially manifesting as a unilateral adrenal incidentaloma. Case Rep Med 2012;2012:849285.
15.
Srivatsa S, Sharma J, Logani S: Intravascular lymphoma: an unusual diagnostic outcome of an incidentally detected adrenal mass. Endocr Pract 2008;14:884-888.
16.
Askarian F, Xu D: Adrenal enlargement and insufficiency: a common presentation of intravascular large B-cell lymphoma. Am J Hematol 2006;81:411-413.
17.
Matsue K, Asada N, Takeuchi M, Yamakura M, Kimura S, Odawara J, Aoki T: A clinicopathological study of 13 cases of intravascular lymphoma: experience in a single institution over a 9-yr period. Eur J Haematol 2008;80:236-244.
18.
Ko YH, Han JH, Go JH, Kim DS, Kwon OJ, Yang WI, Shin DH, Ree HJ: Intravascular lymphomatosis: a clinicopathological study of two cases presenting as an interstitial lung disease. Histopathology 1997;31:555-562.
19.
Suh CH, Kim SK, Shin DH, Chung KY: Intravascular lymphomatosis of the T cell type presenting as interstitial lung disease - a case report. J Korean Med Sci 1997;12:457-460.
20.
Yu H, Chen G, Zhang R, Jin X: Primary intravascular large B-cell lymphoma of lung: a report of one case and review. Diagn Pathol 2012;7:70.
21.
Fujiwara A, Azuma T, Yamanouchi J, Narumi H, Yakushijin Y, Yasukawa M, Hato T, Hamaguchi N, Kadowaki T, Hamada H: Intravascular large B-cell lymphoma presenting as interstitial lung disease. Nihon Naika Gakkai Zasshi 2007;96:2783-2785.
22.
Nakazato T, Sanada Y, Mihara A, Ito C, Aisa Y, Nakamura N: PET-negative pulmonary intravascular large B cell lymphoma diagnosed by a random transbronchial lung biopsy. Ann Hematol 2012;91:811-812.
23.
Shimada K, Kosugi H, Shimada S, Narimatsu H, Koyama Y, Suzuki N, Yuge M, Nishibori H, Iwata Y, Nakamura S, Naoe T, Kinoshita T: Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Int J Hematol 2008;88:149-153.
24.
Kawai N, Okada M, Haba R, Yamamoto Y, Tamiya T: Insufficiency of positron emission tomography and magnetic resonance spectroscopy in the diagnosis of intravascular lymphoma of the central nervous system. Case Rep Oncol 2012;5:339-346.
25.
Hoshino A, Kawada E, Ukita T, Itoh K, Sakamoto H, Fujita K, Mantani N, Kogure T, Tamura J: Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin. Am J Hematol 2004;76:236-239.
26.
Hofman MS, Fields P, Yung L, Mikhaeel NG, Ireland R, Nunan T: Meningeal recurrence of intravascular large B-cell lymphoma: early diagnosis with PET-CT. Br J Haematol 2007;137:386.
27.
Matsue K, Hayama BY, Iwama K, Koyama T, Fujiwara H, Yamakura M, Takeuchi M, O'Uchi T: High frequency of neurolymphomatosis as a relapse disease of intravascular large B-cell lymphoma. Cancer 2011;117:4512-4521.
28.
Hemmaway CJ, Danga A, Igbokwe U, Radunovic A: FDG-PET guided diagnosis of vaginal intravascular diffuse large B-cell lymphoma. Br J Haematol 2012;158:678.
29.
Bazhenova L, Higginbottom P, Mason J: Intravascular lymphoma: a role for single-agent rituximab. Leuk Lymphoma 2006;47:337-341.
30.
Matsue K, Takeuchi M, Uryu H, Koseki M, Asada N, Kaneko Y: Rapid improvement of hypoxemia by the use of rituximab in patients with pulmonary intravascular lymphoma. Leuk Lymphoma 2007;48:197-200.
31.
Takacs I, Eros N, Bene I, Bozso F, Tordai L, Karolyi Z, Radvanyi G, Matolcsy A: Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy. Ann Hematol 2004;83:608-610.
32.
Wu SJ, Chou WC, Ko BS, Tien HF: Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007;92:141-142.
33.
Chang MH, Kim SJ, Kim K, Oh SY, Lee DH, Huh J, Ko YH, Choi CW, Yang DH, Won JH, Kim WS, Suh C: Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. Leuk Lymphoma 2009;50:1119-1125.
34.
Ahn HK, Kim SJ, Yun J, Yi JH, Kim JH, Won YW, Kim K, Ko YH, Kim WS: Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol 2010;91:456-463.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.